Biotech Calendar: Key Dates and Events
BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for October:
JMP Securities Healthcare Focus conference
Cowen & Co. 12 th Annual Therapeutics Conference
FDA approval decision date for Spectrum Pharmaceuticals' (SPPI) colon cancer drug Fusilev.
Presentation at the American Neurological Association meeting of detailed data from the phase III study of Avanir Pharmaceuticals' (AVNR) Zenvia, an experimental drug for the treatment of uncontrollable laughing and crying episodes -- a condition known medically as pseudobulbar affect. Avanir announced positive top-line results from this study in August.
Third-quarter earnings: Johnson & Johnson (JNJ) (before market open) and Gilead Sciences (GILD) (after market close.) Oct. 14
The FDA's Peripheral and Central Nervous System Drug Advisory Committee will convene to review Acorda Therapeutics' (ACOR) fampridine (brand name Amaya). The proposed indication for Amaya is to improve the walking ability of patients with multiple sclerosis. Biogen Idec (BIIB) is Acorda's marketing partner for Amaya.
Take note: The FDA's briefing documents for Amaya should be posted to the agency's web site on Oct. 12 or 13. When available, those documents can be found here.
Third-quarter earnings: Abbott Labs (ABT) (before market open.) Oct. 15
Third-quarter earnings: Cubist Pharmaceuticals (CBST) (after market closes.) Oct. 16-21
The American College of Rheumatology annual meeting in Philadelphia. Noteworthy clinical data expected for presentation includes Pfizer's (PFE) CP-690550 in rheumatoid arthritis and Rigel Pharmaceuticals' (RIGL) R788 in rheumatoid arthritis Oct. 19
FDA approval decision date for Amgen's (AMGN) osteoporosis drug denosumab. If approved, Amgen will market the drug under the brand name Prolia. Oct. 22
FDA's approval decision date for Acorda's drug Amaya. Oct. 24-28
The Obesity Society annual meeting convenes in Washington, D.C. Detailed data from phase III studies of three closely watched weight-loss drugs will be presented at the meeting: Arena Pharmaceuticals' (ARNA) lorcaserin, Vivus' (VVUS) Qnexa and Orexigen Therapeutics' (OREX) Contrave.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV